SCHEMBL10388698

SCHEMBL10388698

CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](n2cnc3c(Cl)ncnc32)[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1O[Si](C)(C)C(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYMP P19971 1/20 0.47
TP53 P04637 2/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
ADORA1 P30542 4/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36
SLC29A1 Q99808 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
DPP4 P27487 1/20 0.35
SLC28A1 O00337 1/20 0.35
MAP3K7 O43318 1/20 0.35
SLC28A2 O43868 1/20 0.35
GAPDH P04406 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL278511 1.00 TYMP (0.47) TYMPTP53ALDH1A1LMNAMAPT
SCHEMBL21382713 0.91 TYMP (0.45) TYMPTP53ALDH1A1LMNAMAPT
SCHEMBL20908820 0.91 TYMP (0.45) TYMPTP53ALDH1A1LMNAMAPT
SCHEMBL11910711 0.90 TYMP (0.46) TYMPTP53ALDH1A1LMNAMAPT
SCHEMBL14424392 0.89 TYMP (0.50) TYMPTP53ALDH1A1LMNAMAPT
SCHEMBL24453499 0.89 TYMP (0.48) TYMPTP53LMNAADORA1MEN1
SCHEMBL22220143 0.88 ADORA1 (0.50) ADORA1MEN1KMT2APDE4DSLC29A1
SCHEMBL21859282 0.88 ADORA1 (0.50) ADORA1MEN1KMT2APDE4DSLC29A1
SCHEMBL6762689 0.88 ADORA1 (0.50) ADORA1MEN1KMT2APDE4DSLC29A1
SCHEMBL21859151 0.88 ADORA1 (0.50) ADORA1MEN1KMT2APDE4DSLC29A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112714649-B Cyclic dinucleotide derivatives and antibody drug conjugates thereof 第一三共株式会社 2024-07-02 CN disclosed
US-20220008549-A1 NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF DAIICHI SANKYO COMPANY, LIMITED (JP) 2022-01-13 US disclosed
US-20220008549-A1 NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF DAIICHI SANKYO COMPANY, LIMITED (JP) 2022-01-13 US disclosed
EP-3848054-A1 NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF Daiichi Sankyo Company, Limited (JP) 2021-07-14 EP disclosed
CN-112714649-A Novel cyclic dinucleotide derivatives and antibody drug conjugates thereof 第一三共株式会社 2021-04-27 CN disclosed
US-4898945-A Process for 6,7-dihydro-5,8-dimethyl-9-fluoro-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1990-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220008549-A1 NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF STING1, CGAS, TLR9 TYMP 1536/4885TP53 2663/4885ALDH1A1 4336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.